Risk factors associated with Helicobacter pylori infection treatment failure in a high prevalence area

Epidemiology and Infection

Volumn 139, Issue 4, 2011, Pages 581-590

  Yakoob, J ^a   Jafri, W ^a   Abbas, Z ^a   Abid, S ^a   Naz, S ^a   Khan, R ^a   Khalid, A ^a  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

Author keywords

cagA; H. pylori; histology; point mutations; vacA

Indexed keywords

AMOXICILLIN; CARBON 14; CLARITHROMYCIN; ESOMEPRAZOLE; RNA 23S; UREASE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BACTERIAL RNA; OMEPRAZOLE; UREA; VIRULENCE FACTOR;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL VIRULENCE; CONTROLLED STUDY; CYTOTOXIN ASSOCIATED GENE; DISEASE ASSOCIATION; DISEASE MARKER; DRUG TREATMENT FAILURE; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRESCRIPTION; RISK ASSESSMENT; TREATMENT DURATION; UREA BREATH TEST; VACUOLATING ASSOCIATED GENE; ADOLESCENT; AGED; BREATH ANALYSIS; GENETICS; HELICOBACTER PYLORI; ISOLATION AND PURIFICATION; MIDDLE AGED; PAKISTAN; PREVALENCE; RISK FACTOR; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BREATH TESTS; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PAKISTAN; POINT MUTATION; PREVALENCE; RISK FACTORS; RNA, BACTERIAL; RNA, RIBOSOMAL, 23S; TREATMENT FAILURE; UREA; VIRULENCE FACTORS; YOUNG ADULT;

EID: 79955676740     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268810001226     Document Type: Article

References (41)

1. Solerman A, et al. Assessment of Helicobacter pylori clarithromycin resistance mutations in archival gastric biopsy samples. Swiss Medical Weekly 2005; 135: 327-332.
2. International Agency for Research on Cancer. Schistosomes, liver flukes and Helicobacter pylori. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 1994; 61: 1-241.
3. Blaser MJ, et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Research 1995; 55: 2111-2115.
4. Bayerdorffer E, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 1995; 345: 1591-1594.
5. Graham DY, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized controlled study. Annals of Internal Medicine 1992; 116: 705-708. (Pubitemid 23033112)
6. Bytzer P, O'Morain C. Treatment of Helicobacter pylori. Helicobacter 2005; 10: 40-46. (Pubitemid 41395406)
7. Megraud F. H. pylori antibiotic resistance : prevalence, importance, and advances in testing. Gut 2004; 53: 1374-1384.
8. Wong BC, et al. Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. Alimentary Pharmacology & Therapeutics 2000; 14: 1529-1535.
9. Broutet N, et al. Risk factors for failure of Helicobacter pylori therapy results of an individual data analysis of 2751 patients. Alimentary Pharmacolagy & Therapeutics 2003; 17: 99-109. (Pubitemid 36140439)
10. Graham DY. Antibiotic resistance in Helicobacter pylori : implications for therapy. Gastroenterology 1998; 115: 1272-1277. (Pubitemid 28485620)
11. Houben MH, et al. A systematic review of Helicobacter pylori eradication therapy: the impact of antimicrobial resistance on eradication rates. Alimentary Pharmacolagy & Therapeutics 1999; 13: 1047-1055. (Pubitemid 29374105)
12. van Doorn LJ, et al. Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment. Gut 2000; 46: 321-326.
13. Occhialini AM, et al. Macrolide resistance in Helicobacter pylori : rapid detection of point mutations and assays of macrolide binding to ribosomes. Antimicrobial Agents and Chemotherapy 1997; 41: 2724-2728.
14. Versalovic JD, et al. Mutations in 23S rRNA are associated with larithromycin resistance in Helicobacter pylori. Antimicrobial Agents and Chemotherapy 1996; 40: 477-480.
15. Hulten K, Gibreel A, Engstrand L. Macrolide resistance in Helicobacter pylori : mechanism and stability in strains from clarithromycin treated patients. Antimicrobial Agents and Chemotherapy 1997; 41: 2550-2553. (Pubitemid 27467573)
16. Taylor DE, et al. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. Antimicrobial Agents and Chemotherapy 1997; 41: 2621-2628. (Pubitemid 27524731)
17. Marais A, et al. Direct detection of Helicobacter pylori resistance to macrolides by a polymerase chain reaction DNA enzyme immunoassay in gastric biopsy specimens. Gut 1999; 44: 463-467. (Pubitemid 29169944)
18. Van Doorn LJ, et al. Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study. Antimicrobial Agents and Chemotherapy 2001; 45: 1500-1504.
19. Van Doorn LJ, et al. Rapid detection, by PCR and reverse hybridization, of mutations in the Helicobacter pylori 23S rRNA gene, associated with macrolide resistance. Antimicrobial Agents and Chemotherapy 1999; 43: 1779-1782.
20. Matsumura M, et al. Rapid detection of mutations in the 23S rRNA gene of Helicobacter pylori that confers resistance to clarithromycin treatment to the bacterium. Journal of Clinical Microbiology 2001; 39: 691-695. (Pubitemid 32150840)
21. Tee W, Lambert JR, Dwyer B. Cytotoxin production by H. pylori from patients with upper gastrointestinal tract disease. Journal of Clinical Microbiology 1995; 33: 1203-1205.
22. van Doorn LJ, et al. Expanding allelic diversity of Helicobacter pylori vacA. Journal of Clinical Microbiology 1998; 36: 2597-2603.
23. Tytgat GNJ. The Sydney system: endoscopic division, endoscopic appearance in gastritis/duodenitis. Journal of Gastroenterology and Hepatology 1991; 6: 223-234.
24. Said RM, et al. Evaluation of a new biopsy urease test : Pronto Dry, for the diagnosis of Helicobacter pylori infection. European Journal of Gastroenterology and Hepatology 2004; 16: 195-199. (Pubitemid 39049657)
25. Price AB. The Sydney System: histological division. Journal of Gastroenterology and Hepatology 1991; 6: 209-222.
26. Rosai J. Rosai and Ackerman's Surgical Pathology, vol. 1, 9th edn. New York: Elsevier, 2004.
27. Van Zwet AA, et al. Sensitivity of Culture compared with that of Polymerase chain reaction for detection of Helicobacter pylori from antral biopsy samples. Journal of Clinical Microbiology 1993; 31: 1918-1920. (Pubitemid 23182604)
28. Mŕnard A, et al. PCR-restriction fragment length polymorphism can also detect point mutation A2142C in the 23S rRNA gene, associated with Helicobacter pylori resistance to clarithromycin. Antimicrobial Agents and Chemotherapy 2002; 46: 1156-1157.
29. Sambrook J, Fritisch EF, Maniatis T. Molecular Cloning: A Laboratory Manual, 2nd edn. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1989, pp. 1847-1855.
30. Björkholm B, et al. Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori. Proceedings of the National Academy of Sciences USA 2001; 98: 14607-14612. (Pubitemid 33121439)
31. Parsonnet J, et al. Risk of gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997; 40: 297-301. (Pubitemid 27145639)
32. Nogueira C, et al. Helicobacter pylori genotypes may determine gastric histopathology. American Journal of Pathology 2001; 158: 647-654. (Pubitemid 32158625)
33. Atherton JC, et al. Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori. Gastroenterology 1997; 112: 92-9. (Pubitemid 27008990)
34. Meining A, et al. Gastric carcinoma risk index in patients infected with Helicobacter pylori. Virchows Archiv 1998; 432: 311-314. (Pubitemid 28171992)
35. Axon ATR, Lynch DAF. Helicobacter pylori, gastric physiology and cancer. European Journal of Gastroenterology and Hepatology 1993; 5: 109-113.
36. Xia HX, Buckley M, Hyde D. Effects of antibiotic resistance on clarithromycin - combined triple therapy for Helicobacter pylori. Gut 1995; 37 (Suppl. 1) : A55.
37. Kim KS, et al. Mutations in the 23S rRNA gene of Helicobacter pylori associated with clarithromycin resistance. Journal of Korean Medical Science 2002; 17: 599-603.
38. Maeda S, et al. Detection of clarithromycin resistant Helicobacter pylori strains by a preferential homoduplex formation assay. Journal of Clinical Microbiology 2000; 38: 210-214. (Pubitemid 30043290)
39. Pan ZJ, et al. Assessment of clarithromycin resistant Helicobacter pylori among patients in Shanghai and Guangzhou, China, by primer-mismatch PCR. Journal of Clinical Microbiology 2002; 40: 259-261.
40. Mohammadi M, et al. Helicobacter pylori antibiotic resistance in Iran. World Journal of Gastroenterology 2005; 11: 6009-6013. (Pubitemid 41749217)
41. Versalovic J, et al. Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. Journal of Antimicrobial Chemotherapy 1997; 40: 283-286. (Pubitemid 27394025)